Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: flexinvesting who wrote (4201)	4/24/2016 11:49:01 AM
From: jesspro	Respond to of 4474

Flex, I share the same sentiment with you, Vid and Puravida. As far as the science side is concerned, we need not search elsewhere for an objective view of ariad drugs as we have in here two very knowledgeable and objective posters in Jaybe and BioM. I truly believe that Denner was very busy last year in planning for the post Harvey era of ariad, that's why we didn't see much press from him last year. His plan started to take effect in the last month of last year and as we could see, there is a different ambience in the way the stock is trading now compared to the last two years. Here's hoping that ariad can live to its potential and sustain its long overdue recovery...jmo.

To: flexinvesting who wrote (4201)	4/24/2016 12:34:31 PM
From: tktom	Read Replies (1) \| Respond to of 4474

However, the next hurdle in my opinion will be having to clear out the shorts as the pps can not go higher (unless there is a severe squeeze) and with that perhaps that is part of "the plan" (a controlled covering) as the current short level has allowed safe day trading along with accumulation to go on for the big boys. I'm not familiar with "controlled covering". Care to explain that, please? And, by definition, shorts that cover will cause the share price to rise, all other conditions being equal.